Key terms

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BMY news

Yesterday 6:00am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF) Yesterday 5:25am ET Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio Apr 08 11:33am ET Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months Apr 08 5:47am ET Bristol-Myers Squibb’s Hold Rating: Balancing KarXT’s Efficacy and Safety with Financial Uncertainties Apr 07 6:44am ET Bristol Myers presents new data from Phase 3 EMERGENT program evaluating KarXT Apr 07 6:34am ET Bristol Myers presents new interim long-term efficacy data from EMERGENT-4 trial Apr 05 9:08am ET Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA Apr 03 4:03pm ET Standard BioTools announces multi-year agreement with Bristol Myers Apr 03 5:56am ET Bristol Myers: European Commission expands approval of Reblozyl Apr 03 5:16am ET Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) Apr 01 7:39am ET Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints Mar 31 5:25am ET Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024 Mar 29 8:30am ET Bristol Myers ends collaboration agreement with Molecular Templates Mar 28 5:20pm ET Bristol Myers Squibb (NYSE:BMY) Slips after Disappointing Drug Trial Mar 28 4:15pm ET Bristol Myers says KRYSTAL-12 trial met primary endpoint in PFS Mar 28 4:02pm ET Bristol Myers: Phase 3 YELLOWSTONE trial did not meet primary endpoint Mar 25 11:46am ET Bristol Myers Squibb call volume above normal and directionally bullish Mar 20 4:52pm ET Bristol Myers’ Abecma approved in the EU for multiple myeloma Mar 20 7:05am ET Bristol Myers says Phase 3 CheckMate -9DW trial met primary endpoint Mar 20 7:01am ET Bristol Myers announces the Phase 3 CheckMate -9DW trial Mar 19 1:32pm ET This radiopharma name seen as ‘poised for takeout’ following Fusion deal Mar 19 12:55pm ET Actinium Pharmaceuticals price target raised to $30 from $20 at Maxim Mar 19 1:37am ET Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results Mar 18 5:52pm ET Gerald Storch Exits, Bristol-Myers Squibb Board Shrinks Mar 18 9:19am ET Arcellx price target raised to $81 from $72 at Needham Mar 18 9:07am ET Bristol Myers completes acquisition of Karuna Therapeutics Mar 18 8:15am ET Perspective Therapeutics announces collaboration agreement with Bristol Myers Mar 18 5:15am ET Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition Mar 15 6:30pm ET Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma Mar 15 12:03pm ET JPMorgan biotech/pharma analysts hold an analyst/industry conference call Mar 15 5:11am ET Bristol Myers announces FDA grants accelerated approval of Breyanzi

BMY Financials

1-year income & revenue

Key terms

BMY Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BMY Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms